

## TEST REPORT : 219127054-02-00

Date: 31 MAY 2011

Tel: +65 68851323 Fax: +65 67784301

Client's Ref: OE1000076

Email: Yang.LI@tuv-sud-psb.sg

**Note:** This report is issued subject to TÜV SÜD PSB's "Terms and Conditions Governing Technical Services".  
The terms and conditions governing the issue of this report are set out as attached within this report.



PSB Singapore

Choose certainty.  
Add value.

### 1. GENERAL

#### 1.1 STUDY TITLE

Acute Dermal Toxicity Study of Bio-X Lullaby

#### 1.2 TEST ITEM IDENTIFICATION

Test item name: Bio-X Lullaby  
Lot No: 20110201  
Sterilization condition: Non-sterile  
Quantity: 220 ml per bottle, 2 bottles  
Date of manufacture: 1 Feb 2011  
Expiry date: 1 Feb 2014

##### 1.2.1 Active Ingredients

(Based on Material Handling Form provided by sponsor)  
Composition: Contains Etofenprox  
Purity: 2.50%w/w

##### 1.2.2. Physical features/propertie

(Based on Material Handling Form provided by sponsor)  
Colour / state: Milky White Emulsion  
Density: 0.997  
pH: 5.83  
Solubility: Soluble in water

#### 1.3 REFERENCE ITEM IDENTIFICATION

Nil



Laboratory:  
TÜV SÜD PSB Pte. Ltd.  
No.1 Science Park Drive  
Singapore 118221

Phone : +65-6885 1333  
Fax : +65-6776 8670  
E-mail: testing@tuv-sud-psb.sg  
www.tuv-sud-psb.sg  
Co. Reg : 199002667R

Regional Head Office:  
TÜV SÜD Asia Pacific Pte. Ltd.  
3 Science Park Drive, #04-01/05  
The Franklin, Singapore 118223  
**TÜV®**



## **2. SPONSOR**

OKADA ECOTECH PTE LTD  
55, Ayer Rajah Crescent  
#03-19/23  
Singapore 139949

## **3. TESTING FACILITY, TESTING SITES AND STAFF**

### **3.1 TESTING FACILITY AND TESTING SITES**

Chemical and Materials  
Testing Services  
TÜV SÜD PSB Pte Ltd  
No 1 Science Park Drive  
Singapore 118221

### **3.2 STAFF**

Study Director  
Study Personnel

Ms Li Yang  
Dr Li Zhao Hui  
Mr Chong Koon Chiang  
Mr Tang Xiao Hua

The above staffs are located at

Chemical and Materials  
Testing Services  
TÜV SÜD PSB Pte Ltd  
No 1 Science Park Drive  
Singapore 118221

## **4. STUDY SCHEDULE AND GUIDELINES**

### **4.1 STUDY SCHEDULE**

|                                |             |
|--------------------------------|-------------|
| Experimental commencement date | 25 Apr 2011 |
| Experimental completion date   | 10 May 2011 |

### **4.2 STUDY GUIDELINES**

4.2.1 OECD Guideline For Testing of Chemicals 402: Acute Dermal Toxicity, adopted on 24 Feb 1987

4.2.2 Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Second revised edition, 2007. Chapter 3.1 Acute toxicity



## 5. QUALITY ASSURANCE STATEMENT

This study was audited by Quality Assurance personnel of Chemical and Materials Testing Services as follows:

1. The study plan was audited on 21 Apr 2011 and the audit report was submitted to Study Director and Test Facility Management on the same day.
2. A process-based audit was conducted between 27 Apr 2011 and 10 May 2011 and the audit report was submitted to Study Director and Test Facility Management on the same day.
3. The raw data and study report were audited on 31 May 2011 and the audit report was submitted to Study Director and Test Facility Management on the same day.

The final report has been found to reflect the raw data obtained.

A handwritten signature in blue ink, appearing to read 'Wan Yu'.

**CHEW WAN YU**  
QUALITY ASSURANCE  
CHEMICAL AND MATERIALS  
TESTING SERVICES

31 May 2011

**DATE**



**6. STATEMENT OF COMPLIANCE**

- 6.1 The procedure of the study complies with the study plan as agreed by the sponsor. The conclusion of the test report is based on the raw data obtained from the study.
- 6.2 This study is in compliance with the regulation of National Advisory Committee on Laboratory Animal Research (NACLAR) of Singapore.
- 6.3 This study is conducted in accordance with Organisation for Economic Co-operation and Development (OECD) Environmental Health and Safety Publications ENV/MC/CHEM(98)17, Series on Principles of Good Laboratory Practice and Compliance Monitoring No.1, OECD Principles of Good Laboratory Practice (as revised in 1997), Paris 1998.

A handwritten signature in black ink, appearing to read 'Li Yang', written over a horizontal line.

**MS LI YANG**  
STUDY DIRECTOR  
CHEMICAL AND MATERIALS  
TESTING SERVICES

31 May 2010

**DATE**

## 7. MATERIAL AND METHODS

### 7.1 PRE-TREATMENT OF TEST ITEM

The test item was used directly for dermal administration without pre-treatment.

### 7.2 PREPARATION OF TEST SUBSTANCE AND NEGATIVE CONTROL

The test item was used for dermal administration directly. So, in this study, the test substance was the test item. No control substance was used in the study.

### 7.3 TEST ANIMALS

|                        |   |
|------------------------|---|
| Species                | Rats  |
| Strain                 | Wistar  |
| Microbiological status | Specific Pathogen Free (SPF)  |
| Age                    | 6 to 8 weeks old  |
| Sex                    | Male, body weight 342 g to 426 g  |
|                        | Female, body weight 208 g to 242 g  |
| Number                 | 5 Male and 5 Female   |
| Source                 | National University of Singapore<br>Centre for Animal Resources (CARE)<br>7 Perahu Road<br>Singapore 718836 |
| Housing Condition      | Individual Ventilated Cage System   |
| Temperature            | 18 - 22°C   |
| Humidity               | 30 - 70%  |
| Food                   | PicoLab <sup>®</sup> Rodent Diet 20 5053  |
| Water                  | Tap water   |

### 7.4 TEST CONDITIONS

#### 7.4.1. Preparation of test animals

7.4.1.1 The test animals were acclimatised for at least 5 days before the test was conducted.

7.4.1.2 Approximately 24 hours before the test, fur in the dorsal area of each animal's trunk was shaved. The shaved area was not less than 10 percent of the body surface.

7.4.1.3 On the dosing day, the animals were weighed prior to dosing. The test substance was administered by topical application on the shaved area of each animal. The dose level was 5000 mg/kg based on the body weight of each animal.

## TEST REPORT : 219127054-02-00

31 MAY 2011



PSB Singapore

7.4.1.4 The test item was applied uniformly over the shaved area which was approximately 10 percent of the total surface area. The test item was then held in contact with the skin using a gauze patch and occlusive dressing. The exposure was conducted for 24 hours.

7.4.1.5 At the end of exposure period, residual test item was removed and cleaned carefully with water.

### 7.4.2 Rationale of selection of limit test

The selection of limit test for this study is due to:

- a) Animal welfare consideration- fewer animals would be used for limit test than full study;
- b) The dermal toxicity of the test item was expected to be around 5000 mg/kg body weight as declared by sponsor.

### 7.4.3 Administration level at 5000 mg/kg body weight

|                |   |
|----------------|---|
| Administration | Topical application                                     |
| Dose level     | 5000 mg/kg body weight based on weight of the test item |
| Dose Interval  | Single dose   |

The details of dose for each animal are as follows:

| Group No | Animal ID No       | Dosing date | Amount of test item used for dosing (g) | Dose level (based on weight of the test item, mg/kg) by body weight |
|----------|--------------------|-------------|---|---|
| Female   | 219127054-02-00-F1 | 26 Apr 2011 | 1.2                                     | 5000  |
|          | 219127054-02-00-F2 |             | 1.0                                     | 5000  |
|          | 219127054-02-00-F3 |             | 1.2                                     | 5000  |
|          | 219127054-02-00-F4 |             | 1.1                                     | 5000  |
|          | 219127054-02-00-F5 |             | 1.2                                     | 5000  |

**TEST REPORT : 219127054-02-00**

31 MAY 2011



PSB Singapore

| Group No | Animal ID No       | Dosing date | Amount of test item used for dosing (g) | Dose level (based on weight of the test item, mg/kg) by body weight |
|----------|--------------------|-------------|---|---|
| Male     | 219127054-02-00-M1 | 26 Apr 2011 | 2.1                                     | 5000  |
|          | 219127054-02-00-M2 |             | 1.7                                     | 5000  |
|          | 219127054-02-00-M3 |             | 1.8                                     | 5000  |
|          | 219127054-02-00-M4 |             | 2.0                                     | 5000  |
|          | 219127054-02-00-M5 |             | 1.8                                     | 5000  |

**7.4.4 Feed and water frequency**

Feed was given throughout dosing and observation period. Feed was given in the chamber in the cage.

Water was given *ad libitum* during dosing and observation period. Water was given through plastic bottle.

**7.4.5 Observation**

The observation of adverse effects was conducted in each animal during the first 30 minutes, periodically during the first 24 hours (with special attention during the first 4 hours), and daily thereafter for a total of 14 days.

On the termination day, all the test animals were euthanized by CO<sub>2</sub> inhalation. Gross necropsy was conducted on all test animals.

**TEST REPORT : 219127054-02-00**

31 MAY 2011



PSB Singapore

**8. TEST RESULTS**

## 8.1. Dose level of each test animal and adverse effects

| Group No | Animal ID          | Body weight (g) | Amount of test item used for dosing (g) | Dose level (based on weight of the test item, mg/kg) by body weight | Adverse effects during and after dosing till endpoint date |
|----------|--------------------|-----------------|---|---|--|
| Female   | 219127054-02-00-F1 | 234             | 1.2                                     | 5000  | No adverse effects observed                                |
|          | 219127054-02-00-F2 | 208             | 1.0                                     | 5000  | No adverse effects observed                                |
|          | 219127054-02-00-F3 | 242             | 1.2                                     | 5000  | No adverse effects observed                                |
|          | 219127054-02-00-F4 | 226             | 1.1                                     | 5000  | No adverse effects observed                                |
|          | 219127054-02-00-F5 | 240             | 1.2                                     | 5000  | No adverse effects observed                                |

| Group No | Animal ID          | Body weight (g) | Amount of test item used for dosing (g) | Dose level (based on weight of the test item, mg/kg) by body weight | Adverse effects during and after dosing till endpoint date |
|----------|--------------------|-----------------|---|---|--|
| Male     | 219127054-02-00-M1 | 426             | 2.1                                     | 5000  | No adverse effects observed                                |
|          | 219127054-02-00-M2 | 342             | 1.7                                     | 5000  | No adverse effects observed                                |
|          | 219127054-02-00-M3 | 356             | 1.8                                     | 5000  | No adverse effects observed                                |
|          | 219127054-02-00-M4 | 398             | 2.0                                     | 5000  | No adverse effects observed                                |
|          | 219127054-02-00-M5 | 368             | 1.8                                     | 5000  | No adverse effects observed                                |

**TEST REPORT : 219127054-02-00**

31 MAY 2011



PSB Singapore

**8.2 Body weight (bw, in gram) and body weight changes (change, in gram) of each animal**

| Group No | Animal ID          | 26-Apr-11<br>Dosing day<br>(Day 0) | 03-May-11<br>(Day 7) |        | 10-May-11<br>(Day 14, Termination<br>Day) |        |
|----------|--------------------|------------------------------------|----------------------|--------|---|--------|
|          |                    |                                    | Body<br>weight       | Change | Body<br>weight                            | Change |
| Female   | 219127054-02-00-F1 | 234.0                              | 250.5                | +16.5  | 271.2                                     | +20.7  |
|          | 219127054-02-00-F2 | 208.1                              | 211.7                | +3.6   | 234.4                                     | +22.7  |
|          | 219127054-02-00-F3 | 242.3                              | 260.3                | +18.0  | 274.3                                     | +14.0  |
|          | 219127054-02-00-F4 | 226.1                              | 242.1                | +16.0  | 254.7                                     | +12.6  |
|          | 219127054-02-00-F5 | 240.0                              | 249.6                | +9.6   | 257.6                                     | +8.0   |

| Group No | Animal ID          | 26-Apr-11<br>Dosing day<br>(Day 0) | 03-May-11<br>(Day 7) |        | 10-May-11<br>(Day 14, Termination<br>Day) |        |
|----------|--------------------|------------------------------------|----------------------|--------|---|--------|
|          |                    |                                    | Body<br>weight       | Change | Body<br>weight                            | Change |
| Female   | 219127054-02-00-M1 | 426.1                              | 417.9                | -8.2   | 392.1                                     | -25.8  |
|          | 219127054-02-00-M2 | 342.2                              | 380.1                | +37.9  | 412.0                                     | +31.9  |
|          | 219127054-02-00-M3 | 356.0                              | 377.2                | +21.2  | 414.1                                     | +36.9  |
|          | 219127054-02-00-M4 | 398.1                              | 402.5                | +4.4   | 432.0                                     | +29.5  |
|          | 219127054-02-00-M5 | 368.0                              | 378.0                | +10.0  | 402.6                                     | +24.6  |

**8.3. Death prior to endpoint**

No animal died during dosing and observation period.



#### 8.4. Onset of toxicity and reversal

No adverse effect was observed in all animals during dosing and observation period.

#### 8.5. Necropsy findings

Necropsy was conducted on all the test animals on the termination day. No abnormality was observed on all the test animals.

### 9. DISCUSSION

Based on the above study,

- a) No animal died during dosing and observation period.
- b) No adverse effects observed on the test animals during dosing and observation period..
- c) Necropsy findings was normal on all animals.

Hence, based on Global Harmonised Classification System (GHS) for acute toxicity hazard categories, LD<sub>50</sub> cut-off value of Bio-X Lullaby, Lot No. 20110201 is more than 5000 mg/kg body weight.

### 10. CONCLUSION

Based on the above results and Global Harmonised Classification System (GHS) for acute toxicity hazard categories, the acute dermal toxicity of the test item- Bio-X Lullaby Lot No: 20110201 as Category 5 or unclassified; the LD<sub>50</sub> value of Bio-X Lullaby Lot No: 20110201 is more than 5000 mg/kg body weight.

**11. DEVIATIONS OF THE STUDY PROCEDURES FROM THE STUDY PROTOCOL**

- 11.1 The body weight of the animals (male and female) used for the study are 208 to 426g instead of 200-300g stated in the study plan. The deviation is due to the animals supplied by local supplier. The deviation does not impact the validity of the study.
- 11.2 The animals used in the study were 6-8 weeks old instead of 8 -12 weeks old stated in the study plan. The deviation is due to the animals supplied by local supplier. The deviation does not impact the validity of the study.
- 11.3 The test item was applied directly on the shaved area of the animals, not moistened with water for injection as stated in the study plan. The deviation is due to the typo error in the study plan. The deviation does not impact the validity of the study.

**12. ARCHIVAL**

The study protocol, study plan, study schedule, all the raw data of experiment, audit report of quality assurance unit and other related documentations and the final test report are stored in the archive of TÜV SÜD PSB Pte Ltd.

**REMARKS:**

1. The above test results relate to the sample of test item as received.

**MR TANG XIAO HUA**  
STUDY PERSONNEL  
CHEMICAL AND MATERIALS  
TESTING SERVICES

**MS LI YANG**  
STUDY DIRECTOR  
CHEMICAL AND MATERIALS  
TESTING SERVICES

# TEST REPORT : 219127054-02-00

31 MAY 2011



PSB Singapore

This Report is issued under the following conditions:

1. Results of the testing/calibration in the form of a report will be issued immediately after the service has been completed or terminated.
2. Unless otherwise requested, this report shall contain only technical results carried out by TÜV SÜD PSB. Analysis and interpretation of the results and professional opinion and recommendations expressed thereupon, if required, shall be clearly indicated and additional fee paid for, by the Client.
3. This report applies to the sample of the specific product/equipment given at the time of its testing/calibration. The results are not used to indicate or imply that they are applicable to other similar items. In addition, such results must not be used to indicate or imply that TÜV SÜD PSB approves, recommends or endorses the manufacturer, supplier or user of such product/equipment, or that TÜV SÜD PSB in any way "guarantees" the later performance of the product/equipment. Unless otherwise stated in this report, no tests were conducted to determine long term effects of using the specific product/equipment.
4. The sample/s mentioned in this report is/are ~~submitted/supplied/manufactured~~ by the Client. TÜV SÜD PSB therefore assumes no responsibility for the accuracy of information on the brand name, model number, origin of manufacture, consignment or any information supplied.
5. Additional copies of the report are available to the Client at an additional fee. No third party can obtain a copy of this report through TÜV SÜD PSB, unless the Client has authorised TÜV SÜD PSB in writing to do so.
6. TÜV SÜD PSB may at its sole discretion add to or amend the conditions of the report at the time of issue of the report and such report and such additions or amendments shall be binding on the Client.
7. All copyright in the report shall remain with TÜV SÜD PSB and the Client shall, upon payment of TÜV SÜD PSB's fees for the carrying out of the tests/calibrations, be granted a license to use or publish the report to the third parties subject to the terms and conditions herein, provided always that TÜV SÜD PSB may at its absolute discretion be entitled to impose such conditions on the license as it sees fit.
8. Nothing in this report shall be interpreted to mean that TÜV SÜD PSB has verified or ascertained any endorsement or marks from any other testing authority or bodies that may be found on that sample.
9. This report shall not be reproduced wholly or in parts and no reference shall be made by the Client to TÜV SÜD PSB or to the report or results furnished by TÜV SÜD PSB in any advertisements or sales promotion.
10. Unless otherwise stated, the tests were carried out in TÜV SÜD PSB Pte Ltd, No.1 Science Park Drive Singapore 118221.

March 2010